<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic approach to the patient with erythrocytosis/polycythemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic approach to the patient with erythrocytosis/polycythemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnostic approach to the patient with erythrocytosis/polycythemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ayalew Tefferi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Erythrocytosis (also called polycythemia) refers to an increased hemoglobin concentration and/or hematocrit in peripheral blood. Diagnosing the specific cause of polycythemia is important for proper management of the patient.</p><p>This topic discusses the causes of erythrocytosis and our approach to evaluation and diagnosis. The approach to confirming a diagnosis of polycythemia vera is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The following terms are important for diagnosing and classifying erythrocytosis; note that we use erythrocytosis and polycythemia interchangeably:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythrocytosis</strong> – Erythrocytosis (polycythemia) is an abnormal elevation of hemoglobin (Hb) and/or hematocrit (Hct) in peripheral blood. We consider the following values to constitute polycythemia [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased hemoglobin </strong>– &gt;16.5 g/dL (10.3 mmol/L) in men or &gt;16.0 g/dL (10.0 mmol/L) in women</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased hematocrit </strong>– &gt;49 percent in men or &gt;48 percent in women</p><p></p><p class="bulletIndent1">Normal values for red blood cell (RBC) parameters in adults are presented in the table  (<a class="graphic graphic_table graphicRef127504" href="/z/d/graphic/127504.html" rel="external">table 1</a>). For children, normal values for RBC parameters vary according to age  (<a class="graphic graphic_table graphicRef57465" href="/z/d/graphic/57465.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relative polycythemia</strong> – Hemoconcentration, or an elevation of Hb and/or Hct due to a decrease in plasma volume alone (ie, without an increase of the RBC mass) is referred to as relative polycythemia. (See <a class="local">'Relative polycythemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absolute polycythemia </strong>–<strong> </strong>Absolute polycythemia refers to an increase of RBC mass, which has multiple causes  (<a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">table 3</a>) and can be categorized as either primary or secondary polycythemia. (See <a class="local">'Causes of absolute polycythemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary polycythemia</strong> – Primary polycythemia refers to an increase of RBC mass caused by a mutation (either acquired or inherited) in RBC progenitor cells. Causes of primary polycythemia are described below. (See <a class="local">'Primary polycythemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary polycythemia</strong> – Secondary polycythemia refers to an increase of RBC mass caused by elevated serum erythropoietin (EPO), as described below. Causes of secondary polycythemia are described below. (See <a class="local">'Secondary polycythemia'</a> below.)</p><p></p><p>Further description of RBC parameters and their determination in a complete blood count are described separately. (See  <a class="medical medical_review" href="/z/d/html/4430.html" rel="external">"Automated complete blood count (CBC)", section on 'RBC parameters'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">PHYSIOLOGY OF ERYTHROPOIESIS</span><span class="headingEndMark"> — </span>Red blood cells (RBCs), like all mature blood cells, are derived from multipotent hematopoietic stem and progenitor cells in the bone marrow through a hierarchical process of lineage commitment and differentiation, as described separately. (See  <a class="medical medical_review" href="/z/d/html/3536.html" rel="external">"Overview of hematopoietic stem cells"</a>.)</p><p>Erythropoietin (EPO) is the primary driver of proliferation and differentiation of RBC progenitors in normal physiology. Ninety percent of circulating EPO in humans is produced by the kidneys as a physiologic response to hypoxia. EPO-producing renal cells detect hypoxic signals due to reduced hemoglobin (anemia)  (<a class="graphic graphic_figure graphicRef53916" href="/z/d/graphic/53916.html" rel="external">figure 1</a>), hypoxemia (eg, reduced oxygen saturation or release by hemoglobin), or impaired oxygen delivery to the kidney (eg, vascular occlusion). EPO production is linked to oxygen delivery via a complex negative feedback loop, as described separately. (See  <a class="medical medical_review" href="/z/d/html/7161.html" rel="external">"Regulation of erythropoiesis"</a>.)</p><p class="headingAnchor" id="H2808502282"><span class="h1">RELATIVE POLYCYTHEMIA</span><span class="headingEndMark"> — </span>Because hemoglobin (Hb) and hematocrit (Hct) reflect the concentration of various RBC components in peripheral blood, a reduction in plasma volume alone, even in the absence of an increase in RBC mass, can cause relative polycythemia (ie, hemoconcentration). The most common reasons for plasma volume depletion are diuretic use, vomiting, or diarrhea.</p><p>Smokers may develop erythrocytosis from a combination of reduced plasma volume and increased RBC mass; these abnormalities generally return to normal with cessation of smoking [<a href="#rid2">2,3</a>]. There is controversy regarding the existence of a distinct entity called Gaisböck's syndrome (also referred to as spurious polycythemia or stress polycythemia), which was classically described as erythrocytosis in tense/anxious patients with hypertension, no splenomegaly, and reduced plasma volume [<a href="#rid4">4-6</a>]. Hypertension with diuretic use and smoking may account for the relative polycythemia in many of these individuals.</p><p class="headingAnchor" id="H57755927"><span class="h1">CAUSES OF ABSOLUTE POLYCYTHEMIA</span><span class="headingEndMark"> — </span>Increased RBC mass (absolute polycythemia) may be caused by autonomous production of RBCs (primary polycythemia) or as a response to elevated serum erythropoietin (EPO; secondary polycythemia). The causes of absolute polycythemia  (<a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">table 3</a>) vary according to the patient population and the clinical setting.</p><p>Evaluation to diagnose the cause of erythrocytosis is described below. (See <a class="local">'Initial evaluation'</a> below.)</p><p class="headingAnchor" id="H3318366874"><span class="h2">Primary polycythemia</span><span class="headingEndMark"> — </span>Primary polycythemia is caused by a mutation (either acquired or inherited) in RBC progenitor cells that results in increased RBC mass. Most commonly, primary polycythemia is caused by an acquired condition, such as polycythemia vera (PV) or another myeloproliferative neoplasm (MPN) in association with <em>JAK2</em> V617F or other mutation. (See  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera"</a> and  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a>.)</p><p>Examples of inherited germline mutations that cause polycythemia include Chuvash polycythemia (mutation of the <em>VHL</em> gene), mutations of the EPO receptor, high-oxygen-affinity hemoglobinopathy, and other rare conditions  (<a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">table 3</a>), which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7164.html" rel="external">"Hemoglobin variants that alter hemoglobin-oxygen affinity"</a> and  <a class="medical medical_review" href="/z/d/html/7106.html" rel="external">"Molecular pathogenesis of congenital erythrocytoses and polycythemia vera"</a>.)</p><p>Evaluation of the patient with suspected primary polycythemia is described below. (See <a class="local">'Suspected PV/MPN'</a> below and <a class="local">'Familial polycythemia'</a> below.)</p><p class="headingAnchor" id="H583346253"><span class="h2">Secondary polycythemia</span><span class="headingEndMark"> — </span>Secondary polycythemia refers to an increase of RBC mass caused by elevated serum EPO. Most often, this is due to an appropriate physiologic response to tissue hypoxia, but secondary polycythemia can also result from autonomous EPO production (eg, an EPO-secreting tumor)  (<a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">table 3</a>), as described in the following sections.</p><p>Evaluation of the cause of elevated EPO in a patient with polycythemia is discussed below. (See <a class="local">'Elevated serum EPO'</a> below.)</p><p class="headingAnchor" id="H1872036956"><span class="h3">Hypoxia-associated polycythemia</span><span class="headingEndMark"> — </span>Polycythemia due to increased EPO in response to hypoxia has numerous possible causes  (<a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">table 3</a>). Most commonly, elevated EPO as a cause of erythrocytosis is due to cardiopulmonary disease (eg, chronic pulmonary disease, cyanotic heart disease, obstructive sleep apnea). Systemic hypoxia may also be caused by residence at high altitude (diminished partial pressure of oxygen in inspired air), while functional tissue hypoxia can result from decreased release of oxygen to peripheral tissues from high oxygen affinity hemoglobin (eg, carbon monoxide [CO] toxicity or rare inherited disorders).</p><p>In smokers, erythrocytosis is often multifactorial, including hypoxia, CO exposure, smoking-related diseases, and volume contraction [<a href="#rid2">2,7</a>].</p><p>Increased EPO production may also be caused by diminished oxygen sensing by the kidney. Examples include reduced blood flow to the kidney (eg, renal artery stenosis) and other intrinsic renal disorders (eg, kidney cysts, hydronephrosis).</p><p>Erythrocytosis occurs in up to one-quarter of patients following renal transplantation. In many patients, the polycythemia is associated with elevated EPO, but other mechanisms may also contribute, including other hematopoietic growth factors, androgens, and activation of the renin-angiotensin system, as described separately. (See  <a class="medical medical_review" href="/z/d/html/7348.html" rel="external">"Kidney transplantation in adults: Posttransplant erythrocytosis"</a>.)</p><p class="headingAnchor" id="H729358037"><span class="h3">Tumor-associated polycythemia</span><span class="headingEndMark"> — </span>Autonomous production of EPO (ie, independent of oxygen sensing) by various tumors can cause paraneoplastic polycythemia. Tumors that are most commonly associated with the overproduction of EPO include hepatocellular carcinoma, renal cell carcinoma, hemangioblastoma, pheochromocytoma, and uterine myomata:</p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocytosis was reported in one-quarter of patients with hepatocellular carcinoma, and this is generally due to secretion of EPO by the cancer [<a href="#rid8">8</a>]. However, elevated serum EPO is more frequently seen than polycythemia, presumably due to the inhibition of erythropoiesis by the malignancy and bleeding (eg, esophageal varices and/or coagulopathy from reduced hepatic production of clotting factors). (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Paraneoplastic syndromes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocytosis occurs in 1 to 5 percent of patients with renal cell carcinoma, and is related to increased production of EPO due to aberrant regulation of hypoxia-inducible transcription factors by mutations of <em>VHL</em>, the gene that encodes the von Hippel-Lindau (VHL) tumor suppressor [<a href="#rid9">9,10</a>]. (See  <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'Erythrocytosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemangioblastomas are slow-growing tumors of the central nervous system that may occur sporadically or can be a manifestation of VHL disease. Mutations of <em>VHL</em> are present in many of these tumors, which may account for impaired sensing of the ambient oxygen tension and paraneoplastic production of EPO. (See  <a class="medical medical_review" href="/z/d/html/5209.html" rel="external">"Hemangioblastoma", section on 'Symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uterine leiomyomata (fibroids) may be associated with secondary polycythemia due to EPO production by the tumor cells [<a href="#rid11">11-13</a>]. (See  <a class="medical medical_review" href="/z/d/html/5486.html" rel="external">"Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history"</a>.)</p><p></p><p class="headingAnchor" id="H1452588260"><span class="h2">Other causes</span><span class="headingEndMark"> — </span>Erythrocytosis may be due to other, miscellaneous causes. </p><p class="bulletIndent1"><span class="glyph">●</span>SGLT2 inhibitors – SGLT2 (sodium-glucose cotransporter-2) inhibitors (eg, <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="116180" href="/z/d/drug information/116180.html" rel="external">ertugliflozin</a>) are antidiabetic agents that are also used in patients with heart failure and chronic renal disease. SGLT2 inhibitors are increasingly recognized as a cause of erythrocytosis. </p><p></p><p class="bulletIndent1">A case series of 30 patients with SGLT2 inhibitor-associated erythrocytosis reported that two-thirds were male, and the median age was 64 years; one-quarter of patients had another erythrocytosis-predisposing factor (eg, sleep apnea, smoking) [<a href="#rid14">14</a>]. Median peak hematocrit was 54.4 percent in males and 51.2 percent in females; serum EPO level was inappropriately normal or increased in all 27 cases in which it was measured. With a median follow-up &gt;2 years, two male patients experienced unstable angina; no other thrombotic events were reported. Discontinuation of the SGLT2 inhibitor led to resolution of erythrocytosis.</p><p></p><p class="bulletIndent1">The mechanism of erythrocytosis by SGLT2 inhibitors may be due to increased EPO production via hypoxia-induced activation of HIF2a, modulation of iron metabolism through hepcidin, and/or hemoconcentration [<a href="#rid15">15,16</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Athletic performance enhancers – Polycythemia may be due to autologous blood transfusion ("blood doping"), self-injection of recombinant EPO, or use of androgens or anabolic steroids as a technique for enhancing athletic performance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cobalt – Cobalt toxicity has been associated with polycythemia, but the mechanism is poorly understood [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>POEMS syndrome – POEMS syndrome (<strong>P</strong>olyneuropathy, <strong>O</strong>rganomegaly, <strong>E</strong>ndocrinopathy, <strong>M</strong>onoclonal plasma cell disorder, <strong>S</strong>kin changes) is a paraneoplastic process that is occasionally associated with polycythemia, but the mechanism is not well understood. (See  <a class="medical medical_review" href="/z/d/html/6662.html" rel="external">"POEMS syndrome", section on 'Polycythemia and thrombocytosis'</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">INITIAL EVALUATION</span><span class="headingEndMark"> — </span>Erythrocytosis may be encountered in the course of evaluating other clinical findings or as an incidental abnormality on a complete blood count (CBC) and differential  (<a class="graphic graphic_algorithm graphicRef140141" href="/z/d/graphic/140141.html" rel="external">algorithm 1</a>). The initial evaluation should enable the clinician to distinguish between relative polycythemia (ie, plasma volume depletion) versus absolute polycythemia (ie, increased red blood cell [RBC] mass). Findings from the initial evaluation, together with the clinical scenario, should direct the subsequent evaluation to establish the underlying diagnosis  (<a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">table 3</a>), as illustrated by the algorithm. (See <a class="local">'Clinical scenarios'</a> below.)</p><p class="headingAnchor" id="H2365785327"><span class="h2">Urgency of evaluation</span><span class="headingEndMark"> — </span>Patients with medical emergencies related to polycythemia (eg, cerebrovascular accident, chest pain) should receive emergency management (eg, hydration, phlebotomy, other measures), as described separately. (See  <a class="medical medical_review" href="/z/d/html/4534.html" rel="external">"Polycythemia vera and secondary polycythemia: Treatment and prognosis", section on 'Specific clinical scenarios'</a>.)</p><p>For other patients, the urgency of evaluation is related to the level of polycythemia and the presence of findings that suggest the presence of polycythemia vera (PV), another myeloproliferative neoplasm (MPN), or other cancers. As an example, a patient with a hematocrit (Hct) ≥60 and pruritus, erythromelalgia, and abdominal fullness should be evaluated promptly because of likelihood of PV and the substantial risk of associated thrombosis or other complication. Conversely, an asymptomatic adult with an Hct of 50 may be evaluated in days to weeks.</p><p class="headingAnchor" id="H2271580441"><span class="h2">CBC/blood smear</span><span class="headingEndMark"> — </span>CBC and differential count may demonstrate abnormalities in RBCs alone or may also reveal findings in white blood cells (WBC) and/or platelets. If available, serial CBCs may reveal the rate of rise (or stability) of hemoglobin (Hb) and Hct.</p><p>Normal values for Hb and Hct in adults  (<a class="graphic graphic_table graphicRef127504" href="/z/d/graphic/127504.html" rel="external">table 1</a>) and children  (<a class="graphic graphic_table graphicRef57465" href="/z/d/graphic/57465.html" rel="external">table 2</a>) are provided separately. World Health Organization (WHO) criteria for erythrocytosis [<a href="#rid1">1</a>] are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased hemoglobin </strong>– &gt;16.5 g/dL in men or &gt;16.0 g/dL in women</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased hematocrit </strong>– &gt;49 percent in men or &gt;48 percent in women</p><p></p><p>Elevation of RBC count alone (ie, not accompanied by increased Hb or Hct) is not a criterion for polycythemia. As an example, an elevated RBC count may be associated with anemia and an increased number of hypochromic, microcytic RBCs, as is typically seen with thalassemia minor. (See  <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'CBC and hemolysis testing'</a>.)</p><p>The blood smear may reveal increased levels of WBCs, eosinophils, or basophils; immature WBC forms; abnormal appearance or an increased number of platelets; or a leukoerythroblastic picture (ie, teardrop-shaped RBCs with circulating nucleated RBCs and/or immature white cells); such abnormalities may suggest an underlying MPN. (See  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">History</span><span class="headingEndMark"> — </span>The history should evaluate:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms that may be caused by the elevated Hb/Hct and/or suggest the presence of PV/MPN [<a href="#rid18">18</a>] include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperviscosity symptoms </strong>–<strong> </strong>Chest or abdominal pain, myalgia and weakness, fatigue, headache, blurred vision, transient loss of vision, paresthesias, slow mentation, and/or a sense of depersonalization</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombosis or bleeding </strong>– Thromboses at unusual sites (eg, mesenteric, hepatic, portal, or retinal veins; arterial thromboses) or excessive bleeding/bruising</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptoms associated with PV </strong>– Unexplained fever, sweats, weight loss; pruritus (especially after bathing [aquagenic pruritus]); erythromelalgia (intense, burning pain and/or redness of the extremities); gout; early satiety due to splenomegaly (see  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera", section on 'Clinical presentation'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional clues to the underlying disorder, including causes and risk factors for secondary polycythemia (eg, volume depletion, hypoxemia, erythropoietin [EPO]-secreting tumor) include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Volume depletion</strong> – Use of diuretics, vomiting, diarrhea, anorexia, lightheadedness, and/or orthostatic symptoms</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardio-pulmonary disease</strong> – Chronic lung disease, dyspnea at rest or with exertion, chronic cough; sleep apnea/hypersomnolence; history of cyanotic heart disease, intracardiac or intrapulmonary shunts; or extensive mucocutaneous telangiectasia (eg, from hereditary hemorrhagic telangiectasia that can be associated with pulmonary arteriovenous malformations) (see  <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">"Medical management of cyanotic congenital heart disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6437.html" rel="external">"Approach to cyanosis in children"</a> and  <a class="medical medical_review" href="/z/d/html/14305.html" rel="external">"Approach to cyanosis in the newborn"</a> and  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Abdomino-pelvic tumor</strong> – Unexpected weight loss, hematuria, abdominal/pelvic pain or fullness (which may point to an intra-abdominal EPO-secreting tumor), history of renal transplantation (see <a class="local">'Tumor-associated polycythemia'</a> above and  <a class="medical medical_review" href="/z/d/html/7348.html" rel="external">"Kidney transplantation in adults: Posttransplant erythrocytosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Social history should evaluate:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Smoking</strong> – Cigarette or cigar smoking, including the number smoked and whether the patient inhales</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Carbon monoxide</strong> – Exposure to carbon monoxide (CO) from smoking, work (eg, engine exhausts or combustion products, work in underground parking lots or tunnels, employment as an auto mechanic, truck or taxicab driver), hobbies, or home life (eg, home heating devices, faulty venting of furnaces or fireplaces) (see  <a class="medical medical_review" href="/z/d/html/322.html" rel="external">"Carbon monoxide poisoning"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>"Blood doping"</strong> – Use of products to improve athletic performance, including androgens (eg, testosterone) or anabolic steroids, self-injection of recombinant erythropoiesis-stimulating agents (eg, <a class="drug drug_general" data-topicid="9410" href="/z/d/drug information/9410.html" rel="external">epoetin alfa</a>), or transfusion of stored autologous blood</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history should examine whether relatives have polycythemic conditions (eg, high oxygen affinity hemoglobinopathies) or documented elevation of Hb or Hct, or other hematologic or systemic syndromes (see <a class="local">'Familial polycythemia'</a> below)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical examination should evaluate manifestations of volume depletion, hyperviscosity, cardio-pulmonary disease, and a possible underlying MPN, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General examination</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cyanosis in the lips, earlobes and fingers, and clubbing in the nailbeds associated with hypoxia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Plethoric facies, dilated lingual or retinal veins, or areas of painful erythema may be seen in patients with PV</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiopulmonary</strong> – Breathing pattern, other respiratory findings, cardiac murmurs or bruits (eg, from pulmonary arteriovenous shunts or right-to-left cardiac shunts) (see <a class="local">'Hypoxia/cardiopulmonary disease'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organomegaly</strong> – Hepatomegaly and/or splenomegaly (from PV or another MPN) or other masses that may be associated with or an EPO-secreting tumor (see <a class="local">'Suspected PV/MPN'</a> below)</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>There is no universal agreement about the essential components of the initial screening evaluation for polycythemia. Our approach is to perform pulse oximetry; measure serum EPO, electrolytes, kidney and liver function tests; and obtain a urinalysis in all patients, unless polycythemia is clearly due to hemoconcentration (ie, volume depletion). We suggest reserving other testing (eg, <em>JAK2</em> and other gene mutation analysis, bone marrow examination, imaging) for selected patients, as guided by the history, physical examination, initial laboratory studies, and clinical scenario  (<a class="graphic graphic_algorithm graphicRef140141" href="/z/d/graphic/140141.html" rel="external">algorithm 1</a>). (See <a class="local">'Clinical scenarios'</a> below.)</p><p>Some experts suggest obtaining a chest X-ray and testing for <em>JAK2</em> V617F in the initial evaluation of <strong>all</strong> patients who do not have apparent relative polycythemia (ie, due to volume contraction).</p><p class="headingAnchor" id="H2266723465"><span class="h3">Pulse oximetry</span><span class="headingEndMark"> — </span>Pulse oximetry should be performed in all patients with polycythemia, as an initial estimate of tissue oxygenation. Pulse oximetry should be performed at rest and after modest exertion. Interpretation of pulse oximetry results is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1612.html" rel="external">"Pulse oximetry", section on 'Interpreting the results'</a>.)</p><p>Hypoxia may suggest the presence of cardiopulmonary disease or other processes as the cause of polycythemia, which should be further evaluated as described below. (See <a class="local">'Hypoxia/cardiopulmonary disease'</a> below.)</p><p>It is important to note that standard pulse oximetry is not an adequate screen for carbon monoxide (CO) exposure, as it does not distinguish carboxyhemoglobin from oxyhemoglobin, as discussed below and separately. (See  <a class="medical medical_review" href="/z/d/html/322.html" rel="external">"Carbon monoxide poisoning", section on 'Diagnosis'</a> and <a class="local">'Hypoxia/cardiopulmonary disease'</a> below.)</p><p class="headingAnchor" id="H1334569437"><span class="h3">Serum erythropoietin (EPO)</span><span class="headingEndMark"> — </span>We suggest obtaining serum EPO for all patients, except when the initial evaluation (ie, history and physical examination, serum chemistries) indicates that the elevation of Hb/Hct is due to volume contraction alone (ie, relative polycythemia). Measurement of serum EPO is important for distinguishing between primary (low or absent EPO) and secondary causes of polycythemia (elevated EPO).</p><p>An increase of serum EPO indicates either an appropriate physiologic response to hypoxia or the autonomous production of EPO (eg, EPO-secreting tumor). Although EPO levels vary with particular conditions, the degree of elevation does not indicate the underlying cause. Nevertheless, EPO levels are generally highest in congenital heart disease with right-to-left shunting or following renal transplantation [<a href="#rid19">19</a>]. Causes of elevated EPO are described above. (See <a class="local">'Secondary polycythemia'</a> above.)</p><p>A low or absent level of serum EPO in the patient with polycythemia is relatively specific for the diagnosis of PV or other MPN. Exceptions include "blood doping" (autologous transfusion to enhance athletic performance), rare cases of congenital polycythemia due to an activating mutation in the EPO receptor [<a href="#rid20">20-22</a>], and occasional patients with post-renal transplant erythrocytosis [<a href="#rid19">19,23</a>]. (See <a class="local">'Primary polycythemia'</a> above.)</p><p class="headingAnchor" id="H903645666"><span class="h3">Other screening labs</span><span class="headingEndMark"> — </span>Other laboratory studies that are useful in the initial evaluation of patients with polycythemia include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum chemistries</strong> – Serum electrolytes and kidney and liver function tests can indicate volume contraction or organ dysfunction that may be associated with renal disease or an underlying tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinalysis</strong> – Hematuria may point to a kidney tumor or other renal abnormalities.</p><p></p><p class="headingAnchor" id="H3102754506"><span class="h2">Are JAK2 testing/bone marrow examination required for all?</span><span class="headingEndMark"> — </span>We suggest <strong>not</strong> testing for <em>JAK2</em> mutation and/or bone marrow examination in all patients with polycythemia.</p><p>We selectively perform <em>JAK2</em> mutation testing in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with clinical findings from the history and physical examination that suggest PV or other MPN (eg, pruritus, erythromelalgia, arterial or venous thrombosis, unexplained bleeding/excessive bruising) (see <a class="local">'Suspected PV/MPN'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with low or normal serum EPO and no evidence of volume contraction (ie, relative polycythemia)</p><p></p><p>Evaluation of <em>JAK2</em> mutation testing and other molecular evaluation for PV and MPNs is discussed below and separately. (See <a class="local">'Suspected PV/MPN'</a> below and  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera", section on 'JAK2 mutations'</a>.)</p><p>We perform a bone marrow examination only when there is clinical suspicion or molecular evidence for PV or other MPN, as described above. In those settings, bone marrow biopsy is important for evaluation of myelofibrosis, acute myeloid leukemia, or other complications of these disorders. (See <a class="local">'Suspected PV/MPN'</a> below.)</p><p class="headingAnchor" id="H4127637552"><span class="h1">CLINICAL SCENARIOS</span><span class="headingEndMark"> — </span>The initial evaluation provides findings that direct further evaluation and enable the clinician to define the underlying cause of erythrocytosis, as described in the sections below. (See <a class="local">'Initial evaluation'</a> above.)</p><p class="headingAnchor" id="H1788388173"><span class="h2">Resolution of polycythemia</span><span class="headingEndMark"> — </span>If a repeat complete blood count (CBC) reveals resolution of polycythemia, and no findings from the initial evaluation that suggest polycythemia vera (PV), other myeloproliferative neoplasm (MPN), or other malignancy, no further evaluation is required. In many such cases, the initial evaluation will identify a likely explanation for transient polycythemia. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocytosis resolved after management of dehydration from diarrhea or diuretic use; in this setting, the diagnosis is relative polycythemia due to plasma volume contraction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocytosis resolved in association with improvement of hypoxia after smoking cessation or management of obstructive sleep apnea in a patient with elevated serum erythropoietin (EPO).</p><p></p><p class="headingAnchor" id="H1548953249"><span class="h2">Suspected volume depletion</span><span class="headingEndMark"> — </span>When hemoglobin (Hb) and/or hematocrit (Hct) are elevated due to volume depletion, rather than an increase in RBC mass, the patient is considered to have relative polycythemia. In this setting, evaluation and management are primarily focused on identifying the underlying cause, managing symptoms, and correcting volume depletion, fluid loss, and associated electrolyte abnormalities.</p><p>Identification of volume depletion is generally based on the initial clinical evaluation, because direct methods for estimating blood volume are not widely available. Examples of clinical findings that suggest volume depletion are thirst, postural dizziness, loss of skin turgor, orthostatic hypotension, and elevated blood urea nitrogen (BUN)/creatinine, but these findings are not always reliable in older individuals. Clinical evaluation of volume depletion is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2298.html" rel="external">"Etiology, clinical manifestations, and diagnosis of volume depletion in adults", section on 'Clinical manifestations'</a>.)</p><p>When volume depletion is suspected as the cause of relative polycythemia, a repeat CBC after fluid restoration or reduction of diuretics should reveal improvement in Hb/Hct. No further evaluation is required if polycythemia resolved and the initial clinical evaluation did not reveal findings associated with PV/MPN (eg, constitutional symptoms, pruritus, erythromelalgia, splenomegaly, or thromboses) or other cancer. (See <a class="local">'History'</a> above.)</p><p>In this setting, symptoms and complications are more commonly associated with volume depletion than with the level of Hb/Hct. Consequently, a balance should be struck between the patient's overall condition (eg, fluid status) and a desire to normalize hematologic values. However, if polycythemia persists after restoration of clinical euvolemia, the clinician should remain suspicious that other causes are contributing to erythrocytosis.</p><p>There is controversy regarding the existence of a distinct entity called Gaisböck's syndrome (also referred to as spurious polycythemia or stress polycythemia) [<a href="#rid4">4-6</a>]. Classically, this was described as polycythemia in anxious patients with hypertension, no splenomegaly, and reduced plasma volume. However, hypertension with diuretic use and smoking may account for the relative polycythemia in many of these individuals. Smoking should be discontinued in all such patients.</p><p>Volume contraction contributes to polycythemia in smokers. A clue to the presence of smoking-related polycythemia is a reduction in Hct by ≥4 percent within a few days of smoking cessation [<a href="#rid2">2</a>].</p><p>Although this testing is no longer widely available, the RBC mass can be determined directly by infusion of the patient's own RBCs labeled with a radioactive isotope (eg, Tc99m, Cr51), while the plasma volume is simultaneously and directly determined following infusion of isotopically-labeled human albumin [<a href="#rid24">24-27</a>]. Similar methods have been developed using non-radioactive labels (eg, carbon monoxide, <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">biotin</a>) [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H1679004627"><span class="h2">Elevated serum EPO</span><span class="headingEndMark"> — </span>Serum EPO may be elevated as an appropriate physiologic response to hypoxia or because of inappropriate, autonomous production of EPO (eg, EPO-secreting tumor). Distinguishing between these causes for elevated EPO is based on findings from the history and physical examination and the results of pulse oximetry, as described below.</p><p class="headingAnchor" id="H2835634271"><span class="h3">Hypoxia/cardiopulmonary disease</span><span class="headingEndMark"> — </span>A cardiopulmonary cause for secondary polycythemia is diagnosed by the clinical evaluation together with hypoxia and elevated serum EPO. Management should focus on improving the underlying cause of hypoxia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigating the cause</strong> – Clinical findings that suggest a cardiopulmonary cause for polycythemia include dyspnea, cough, cyanosis, symptoms associated with obstructive sleep apnea (OSA; eg, snoring, wake-time sleepiness, nocturnal choking or gasping), cyanotic heart disease, intracardiac or intrapulmonary shunts, and extensive mucocutaneous telangiectasia (suggestive of hereditary hemorrhagic telangiectasia; HHT). (See <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent1">In-laboratory or home sleep apnea testing should be performed if the clinical history suggests OSA, as described separately. </p><p></p><p class="bulletIndent1">Hypoxia may also be related to residence at high altitude or chronic carbon monoxide (CO) exposure. Carboxyhemoglobin should be measured in patients with a substantial smoking history or potential chronic exposure to CO, because standard pulse oximetry, which does not distinguish between carboxyhemoglobin and oxyhemoglobin, is not sufficient to diagnose CO toxicity. Levels of carboxyhemoglobin ≥5 percent strongly suggest polycythemia caused by CO poisoning; this diagnosis is confirmed if Hb/Hct normalize within two to three months after cessation of exposure [<a href="#rid2">2,3</a>]. Other aspects of the clinical presentation and diagnosis of chronic CO toxicity are presented separately. (See  <a class="medical medical_review" href="/z/d/html/322.html" rel="external">"Carbon monoxide poisoning"</a>.)</p><p></p><p class="bulletIndent1">In children and in adults, congenital cyanotic heart disease may cause secondary polycythemia. Evaluation and management of such disorders are described separately. (See  <a class="medical medical_review" href="/z/d/html/14305.html" rel="external">"Approach to cyanosis in the newborn"</a> and  <a class="medical medical_review" href="/z/d/html/6437.html" rel="external">"Approach to cyanosis in children"</a> and  <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">"Medical management of cyanotic congenital heart disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management is based on correcting or improving the underlying cause of hypoxia. Examples include supplemental oxygen and/or bronchodilators for lung disease, techniques for improving OSA, and repair of cardiac or pulmonary shunts. Smoking should be discontinued and exposure to CO eliminated.</p><p></p><p class="bulletIndent1">Because erythrocytosis caused by cardiopulmonary disease is an appropriate response to tissue hypoxia, attempts to reduce RBC mass by phlebotomy may exacerbate tissue hypoxia. Consequently, phlebotomy is not often utilized unless there is extreme elevation of Hct (eg, ≥65 percent) or symptoms attributable to increased blood volume/hyperviscosity (eg, fatigue, headache, blurred vision, transient loss of vision, paresthesias, slow mentation). </p><p></p><p class="bulletIndent1">Management of secondary erythrocytosis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4534.html" rel="external">"Polycythemia vera and secondary polycythemia: Treatment and prognosis", section on 'Secondary polycythemia'</a>.)</p><p></p><p class="headingAnchor" id="H3700722669"><span class="h3">Other causes of EPO elevation</span><span class="headingEndMark"> — </span>Other causes of erythrocytosis should be considered if serum EPO is elevated, but clinical evaluation and pulse oximetry do not suggest a cardiopulmonary cause (as described above). The evaluation should seek to distinguish between renal causes for elevated EPO (eg, renal artery stenosis, post-renal transplantation) versus autonomous production by an EPO-secreting tumor.</p><p>Findings from the initial clinical evaluation that might suggest an EPO-producing tumor include abdominal pain or fullness, menorrhagia, constitutional symptoms, unexplained weight loss, neurologic abnormalities, or hematuria. Erythrocytosis in the setting of significant menorrhagia may be a clue to fibroids as the source of elevated EPO. Further diagnostic testing for an EPO-producing tumor should include CT (computerized tomography) of the abdomen and pelvis, CT or MRI (magnetic resonance imaging) of the brain, or other imaging modality. Cancer diagnosis generally requires a biopsy of the suspected mass. (See <a class="local">'Tumor-associated polycythemia'</a> above.)</p><p>The diagnostic evaluation for renal artery stenosis or other renal disease as a cause of elevated EPO is guided by the clinical setting and presence of hypertension, renal insufficiency, or abnormal urinalysis, as described separately. (See  <a class="medical medical_review" href="/z/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension", section on 'Selecting a diagnostic test'</a>.)</p><p class="headingAnchor" id="H738901726"><span class="h2">Suspected PV/MPN</span><span class="headingEndMark"> — </span>PV should be suspected in patients with MPN-related symptoms (eg, headache, dizziness, visual disturbances, pruritus, early satiety) or complications (eg, thrombosis, bleeding); a blood smear that reveals leukocytosis, increased levels of eosinophils or basophils, immature white blood cell forms, an increased number or abnormal appearance of platelets, or a leukoerythroblastic picture; or polycythemia in association with low or absent EPO. Evaluation for PV requires molecular testing (eg, for <em>JAK2</em> mutation) and bone marrow examination.</p><p>Diagnosis of PV, according to World Health Organization criteria  (<a class="graphic graphic_table graphicRef110224" href="/z/d/graphic/110224.html" rel="external">table 4</a>), is based on elevation of Hb/Hct, a bone marrow biopsy that shows hypercellularity with panmyelosis, and <em>JAK2 </em>V617F or <em>JAK2</em> exon 12 mutation. Further details of the diagnostic evaluation of PV are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera", section on 'Diagnosis'</a>.)</p><p>Polycythemia may also be a manifestation of essential thrombocythemia (ET), primary myelofibrosis, or chronic myeloid leukemia. Distinguishing PV from ET or other MPN may be difficult at times, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H1545862431"><span class="h2">Familial polycythemia</span><span class="headingEndMark"> — </span>Familial polycythemia should be suspected when the onset of polycythemia is in childhood or there is a positive family history of polycythemia.</p><p>Laboratory investigation usually begins with the determination of the oxygen pressure at 50 percent Hb saturation (P<sub>50</sub>)  (<a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">figure 2</a>). A low P<sub>50</sub> suggests a high oxygen affinity hemoglobinopathy, congenital methemoglobinemia, bisphosphoglyceromutase deficiency, or other rare conditions. (See  <a class="medical medical_review" href="/z/d/html/7164.html" rel="external">"Hemoglobin variants that alter hemoglobin-oxygen affinity"</a> and  <a class="medical medical_review" href="/z/d/html/7106.html" rel="external">"Molecular pathogenesis of congenital erythrocytoses and polycythemia vera"</a>.)</p><p>A normal P<sub>50</sub> in a patient with a familial polycythemia may be caused by a variety of rare syndromes caused by inherited (germline) mutations [<a href="#rid30">30</a>]. Examples include primary familial and congenital polycythemia, which may be caused by an activating mutation of the EPO-receptor (EPOR) or other mutations; Chuvash polycythemia, caused by variants or deletions of <em>VHL</em>; or other genetic disorders, as described separately. (See  <a class="medical medical_review" href="/z/d/html/7106.html" rel="external">"Molecular pathogenesis of congenital erythrocytoses and polycythemia vera"</a> and  <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a>.)</p><p class="headingAnchor" id="H66307014"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116776.html" rel="external">"Society guideline links: Myeloproliferative neoplasms"</a>.)</p><p class="headingAnchor" id="H3768943672"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Erythrocytosis (also called polycythemia) describes an increased hemoglobin (Hb) concentration and/or hematocrit (Hct) in blood. Polycythemia can be due to an increased red blood cell (RBC) mass and/or hemoconcentration (decreased plasma volume). (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1">Thresholds for erythrocytosis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adults</strong> –  (<a class="graphic graphic_table graphicRef127504" href="/z/d/graphic/127504.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Males</strong> – Hb &gt;16.5 g/dL or Hct &gt;49 percent </p><p class="bulletIndent3"><span class="glyph">-</span><strong>Females</strong> – Hb &gt;16.0 g/dL or Hct &gt;48 percent </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong> – Normal values vary with age and sex  (<a class="graphic graphic_table graphicRef57465" href="/z/d/graphic/57465.html" rel="external">table 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physiology of erythropoiesis</strong> – Erythropoietin (EPO) is the primary driver of RBC mass; 90 percent of circulating EPO is produced by the kidneys in response to hypoxia. (See <a class="local">'Physiology of erythropoiesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – Initial evaluation for erythrocytosis  (<a class="graphic graphic_algorithm graphicRef140141" href="/z/d/graphic/140141.html" rel="external">algorithm 1</a>) should distinguish volume contraction from increased RBC mass, based upon (see <a class="local">'Initial evaluation'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History and physical examination</p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count (CBC) and differential count</p><p class="bulletIndent2"><span class="glyph">•</span>Serum electrolytes and kidney function tests</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Status after achieving euvolemia</strong> – Volume-depleted patients should be volume repleted, with further evaluation guided by the resultant level of Hb/Hct. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normalization with euvolemia</strong> – For Hb/Hct that normalizes after volume repletion (ie, relative polycythemia), no further evaluation for polycythemia is needed. (See <a class="local">'Relative polycythemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent polycythemia</strong> – For polycythemia that persists after correction of volume loss (ie, absolute polycythemia), we obtain:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pulse oximetry</strong></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Serum EPO</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical scenarios</strong> – Results from pulse oximetry and serum EPO guide further evaluation and likely diagnoses  (<a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">table 3</a>) (see <a class="local">'Clinical scenarios'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decreased O</strong><strong><sub>2</sub></strong><strong> saturation and/or elevated EPO</strong> – Hypoxia or elevated EPO indicates secondary polycythemia; possible causes include  (<a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hypoxia/cardiopulmonary causes</strong> – Chronic lung disease, right-to-left cardiac shunt, sleep apnea, high altitude, carbon monoxide poisoning, and other disorders that cause hypoxia and elevated EPO </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Kidney-associated</strong> – Elevated EPO due to renal artery stenosis or post-kidney transplantation </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Miscellaneous causes</strong> – SGLT2 (sodium-glucose cotransporter-2) inhibitors, EPO-producing tumors, blood-doping</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adequate O</strong><strong><sub>2</sub></strong><strong> saturation and low or normal EPO</strong> – These patients should be evaluated for polycythemia vera (PV) and other myeloproliferative neoplasms (MPNs). Testing should begin wi<em>th JAK2</em> V617F; if negative, the evaluation should include other mutations <em>of JAK2</em>,<em> MPL</em>,<em> CALR</em>, and<em> BCR::ABL1</em> and may include bone marrow examination. Evaluation and diagnostic criteria for PV and other MPNs are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera"</a> and  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a> and  <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">"Clinical manifestations and diagnosis of chronic myeloid leukemia"</a>.) </p><p></p><p class="bulletIndent2">Testing for rare inherited mutations of Hb or metabolic disorders should be considered if an MPN is not found.</p><p></p><p class="headingAnchor" id="H4154839639"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Smith JR, Landaw SA. Smokers' polycythemia. N Engl J Med 1978; 298:6.</a></li><li><a class="nounderline abstract_t">Aitchison R, Russell N. Smoking--a major cause of polycythaemia. J R Soc Med 1988; 81:89.</a></li><li><a class="nounderline abstract_t">LAWRENCE JH, BERLIN NI. Relative polycythemia; the polycythemia of stress. Yale J Biol Med 1952; 24:498.</a></li><li><a class="nounderline abstract_t">Berlin NI, Wasserman LR. Polycythemia vera: a retrospective and reprise. J Lab Clin Med 1997; 130:365.</a></li><li><a class="nounderline abstract_t">Brown SM, Gilbert HS, Krauss S, Wasserman LR. Spurious (relative) polycythemia: a nonexistent disease. Am J Med 1971; 50:200.</a></li><li><a class="nounderline abstract_t">Weaver LK. Clinical practice. Carbon monoxide poisoning. N Engl J Med 2009; 360:1217.</a></li><li><a class="nounderline abstract_t">Kew MC, Fisher JW. Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 1986; 58:2485.</a></li><li><a class="nounderline abstract_t">Da Silva JL, Lacombe C, Bruneval P, et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 1990; 75:577.</a></li><li><a class="nounderline abstract_t">Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002; 99:3562.</a></li><li><a class="nounderline abstract_t">Yoshida M, Koshiyama M, Fujii H, Konishi M. Erythrocytosis and a fibroid. Lancet 1999; 354:216.</a></li><li><a class="nounderline abstract_t">Suzuki M, Takamizawa S, Nomaguchi K, et al. Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis. Br J Haematol 2001; 113:49.</a></li><li><a class="nounderline abstract_t">LevGur M, Levie MD. The myomatous erythrocytosis syndrome: a review. Obstet Gynecol 1995; 86:1026.</a></li><li><a class="nounderline abstract_t">Gangat N, Szuber N, Alkhateeb H, et al. JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood 2021; 138:2886.</a></li><li><a class="nounderline abstract_t">Mazer CD, Hare GMT, Connelly PW, et al. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation 2020; 141:704.</a></li><li><a class="nounderline abstract_t">Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Paustenbach DJ, Tvermoes BE, Unice KM, et al. A review of the health hazards posed by cobalt. Crit Rev Toxicol 2013; 43:316.</a></li><li><a class="nounderline abstract_t">Keohane C, McMullin MF, Harrison C. The diagnosis and management of erythrocytosis. BMJ 2013; 347:f6667.</a></li><li><a class="nounderline abstract_t">Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994; 24:1.</a></li><li><a class="nounderline abstract_t">Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 1997; 34:70.</a></li><li><a class="nounderline abstract_t">Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 1997; 89:4628.</a></li><li><a class="nounderline abstract_t">Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90:2057.</a></li><li><a class="nounderline abstract_t">Brox AG, Mangel J, Hanley JA, et al. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins. Transplantation 1998; 66:1053.</a></li><li><a class="nounderline abstract_t">Pearson TC, Messinezy M. Investigation of patients with polycythaemia. Postgrad Med J 1996; 72:519.</a></li><li><a class="nounderline abstract_t">Bernard PJ. Measurement of red-cell and plasma volumes. Nouv Rev Fr Hematol 1994; 36:155.</a></li><li><a class="nounderline abstract_t">Fairbanks VF, Klee GG, Wiseman GA, et al. Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods. Blood Cells Mol Dis 1996; 22:169.</a></li><li><a class="nounderline abstract_t">Holme S, Elfath MD, Heaton A, et al. Prediction of red cell and blood volumes distribution by various nomograms: do current nomograms overestimate? Transfusion 2008; 48:910.</a></li><li><a class="nounderline abstract_t">Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely. Eur J Appl Physiol 2005; 95:486.</a></li><li><a class="nounderline abstract_t">Mock DM, Matthews NI, Strauss RG, et al. Red blood cell volume can be independently determined in vitro using sheep and human red blood cells labeled at different densities of biotin. Transfusion 2009; 49:1178.</a></li><li><a class="nounderline abstract_t">Prchal JT, Sokol L. "Benign erythrocytosis" and other familial and congenital polycythemias. Eur J Haematol 1996; 57:263.</a></li></ol></div><div id="topicVersionRevision">Topic 7075 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/618465" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Smokers' polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3346863" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Smoking--a major cause of polycythaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14951396" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Relative polycythemia; the polycythemia of stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9358074" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Polycythemia vera: a retrospective and reprise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5545457" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Spurious (relative) polycythemia: a nonexistent disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19297574" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical practice. Carbon monoxide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2429757" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Serum erythropoietin concentrations in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2297568" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986208" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421304" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Erythrocytosis and a fibroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328280" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7501327" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The myomatous erythrocytosis syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34653249" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31707794" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32044999" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23656559" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A review of the health hazards posed by cobalt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24246666" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The diagnosis and management of erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023814" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Posttransplant erythrocytosis: an enigma revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9025165" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Erythropoietin receptor mutations and human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9192789" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292543" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9808491" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8949586" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Investigation of patients with polycythaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036132" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Measurement of red-cell and plasma volumes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8931957" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18208408" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prediction of red cell and blood volumes distribution by various nomograms: do current nomograms overestimate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16222540" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220818" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Red blood cell volume can be independently determined in vitro using sheep and human red blood cells labeled at different densities of biotin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8982288" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : "Benign erythrocytosis" and other familial and congenital polycythemias.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
